The MS remyelinating drug bexarotene (an RXR agonist) promotes induction of human Tregs and suppresses Th17 differentiation in vitro
- DOI
- 10.17863/cam.88269
- Published
- 2021
- Container
- Not recorded
- Publisher
- Cold Spring Harbor Laboratory
- Open access
- yes
Credibility signals
limited evidence Score 47/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- supportingPublication license: A publication license was supplied: https://creativecommons.org/licenses/by/4.0/legalcode. Presence improves reuse transparency, not research validity.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.17863/cam.88269,
title = {The MS remyelinating drug bexarotene (an RXR agonist) promotes induction of human Tregs and suppresses Th17 differentiation in vitro},
author = {Gaunt, Christof and Rainbow, Daniel and Mackenzie, Ruairi and Jarvis, Lorna and Mousa, Hani and Cunniffe, Nicholas and Georgieva, Zoya and Brown, J William and Coles, Alasdair and Jones, Joanne},
year = {2021},
doi = {10.17863/cam.88269},
url = {https://doi.org/10.17863/cam.88269}
}RIS
TY - JOUR TI - The MS remyelinating drug bexarotene (an RXR agonist) promotes induction of human Tregs and suppresses Th17 differentiation in vitro AU - Gaunt, Christof AU - Rainbow, Daniel AU - Mackenzie, Ruairi AU - Jarvis, Lorna AU - Mousa, Hani AU - Cunniffe, Nicholas AU - Georgieva, Zoya AU - Brown, J William AU - Coles, Alasdair AU - Jones, Joanne PY - 2021 DO - 10.17863/cam.88269 UR - https://doi.org/10.17863/cam.88269 ER -
APA
Christof, G., Daniel, R., Ruairi, M., Lorna, J., Hani, M., Nicholas, C., Zoya, G., William, B. J., Alasdair, C., & Joanne, J. (2021). The MS remyelinating drug bexarotene (an RXR agonist) promotes induction of human Tregs and suppresses Th17 differentiation in vitro. https://doi.org/10.17863/cam.88269
Source records
- datacite · retrieved 2026-11-10T09:19:47.748Z